Navigation Links
Data from Clinical Studies of bioTheranostics' CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
Date:6/7/2011

SAN DIEGO, June 7, 2011 /PRNewswire/ -- bioTheranostics, Inc., a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID®, and Breast Cancer Index(SM). Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago.

On June 6, scientists from bioTheranostics and the Institut Gustave-Roussy (France) presented results from a study evaluating the utility of the Breast Cancer Index(SM) (BCI) for predicting pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy.  In the study, patients with a high BCI score had a more favorable response to standard chemotherapies such as anthracycline and taxane (P=0.02).

"Patients determined as high-risk by BCI had a 10-fold greater probability of pCR with the chemotherapy regimen when compared to the low risk patients," said Mark Erlander, Ph.D., chief scientific officer, bioTheranostics. "These results suggest that BCI is predictive of chemotherapy response."

bioTheranostics also presented diagnostic utility data for CancerTYPE ID® from a study of 754 metastatic cancer cases.  The results showed that pre-CancerTYPE ID® pathological workup involved a mean of seven immunohistochemistry (IHC) stains to identify the cancer site of origin.  Increasing the number of IHC stains beyond seven lengthened the diagnostic process without improving the accuracy of the final result.

"Quickly and accurately diagnosing the site of origin is critical in the care of metastatic cancer patients," said Richard Ding, chief executive officer, bioTheranostics.  "This study illustrated that the current diagnostic process is not standardized and often time- consuming."  In the study, CancerTYPE ID required only five days of lab processing to predict a
'/>"/>

SOURCE bioTheranostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tocagens First-in-Human Clinical Trial of Toca 511 Enrolling Patients with High Grade Glioma
2. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
3. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
4. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
5. Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
6. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
7. Spherix Drug Candidate SPX-106 Shows Statistically Significant Reductions in Serum Triglycerides in Preclinical Testing
8. IDEV Technologies Announces Completion of SUPERB Clinical Trial Enrollment
9. Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase
10. PLC Ramps Up for U.S. Clinical Trial of RenalGuard®
11. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... ALBANY, New York , July 11, 2014 /PRNewswire/ ... published by Transparency Market Research "Endoscopy Devices Market (Endoscopes, ... Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019" the ... billion in 2012 and is expected to grow at ... reach an estimated value of USD 36.9 billion in ...
(Date:7/11/2014)... , July 11, 2014 ... to Safety & Health Expo 2014 were ... move to London , ... attending exhibition.          ... http://photos.prnewswire.com/prnh/20140711/696892-a )      (Photo: ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
(Date:7/11/2014)... 11, 2014 Operators and ... billion in fuel costs now that model ... current GHG standards are phasing in ... upon themselves to install new features into ... reduction technologies , 2.    Efficient driveline components which ...
(Date:7/11/2014)... July 11, 2014 Ticket Down is ... Concord Pavilion . When it comes to the summer concert ... The 37-year-old Georgia native is one of the biggest names in ... business. Bryan is currently out on his “That’s My Kind of ... stops the tour will be making through the rest of the ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Global enterprises ... services to outsource day-to-day management activities. Managed services offer ... additional expenses. The economic slowdown resulted into rising operational ... and expenses is considered to be the global market ... future. , The global managed services market is estimated ...
(Date:7/11/2014)... The Miriam Hospital have found that people with ... rates of smoking than those without mobility impairments. ... to attempt quitting than those without mobility impairments, ... for this population. The study and its findings ... the American Journal of Public Health . ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Delaying surgery to repair damage to ... the middle of the knee -- could increase a young ... the medical records of 130 patients, aged 8 to 16, ... surgery less than six weeks after their injury, 37 had ... surgery more than three months after their injury. The ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2
... ... tests green product performance on real-world soils. , ... Lowell, MA (PRWEB) April 22, 2010 -- The ... Massachusetts Lowell (UMass Lowell) TURI Lab as a High Performance Cleaning Product (HPCP) under ...
... The New Mexico ... ... Tamaya Mist Spa & Salon at the Hyatt Regency Tamaya Resort & Spa has recently ... the nation,s leading travel magazines. The New Mexico spa resort was ranked as the ...
... Major ... cannabis , ... April 22, 2010 -- MarijuanaDoctors.com, the nation’s leading online medical marijuana evaluations company, and ... forces to help patients across the country find quality medical marijuana doctors ...
... ... coverage – just the beginning. , ... Waterloo, IA (Vocus) April 21, 2010 -- VGM ... including: Home Medical Equipment, Durable Medical Equipment, Orthotic, Prosthetic, Medical Device Manufacturers, Medical ...
... According to a study conducted at Thomas Jefferson ... a cost-effective alternative to invasive cardiac catheterization in the ... but a less than 50 percent chance of actually ... will be published in the May issue of the ...
... before the Medicare Evidence Development and Coverage Advisory ... treatment of localized prostate cancer. MEDCAC provides advice ... Medicaid Services for what is covered by Medicare ... focused on the risks, benefits and outcomes of ...
Cached Medicine News:Health News:IEHA and UMass Lowell Recognize Activeion as a High Performance Cleaning Product 2Health News:IEHA and UMass Lowell Recognize Activeion as a High Performance Cleaning Product 3Health News:Leading New Mexico Resort Spa At Hyatt Regency Tamaya Ranked Among The Country's Best By Conde Nast Traveler 2Health News:Leading New Mexico Resort Spa At Hyatt Regency Tamaya Ranked Among The Country's Best By Conde Nast Traveler 3Health News:MarijuanaDoctors.com and PotLocator.com Form Alliance, Expand Medical Marijuana iPhone App 2Health News:MarijuanaDoctors.com and PotLocator.com Form Alliance, Expand Medical Marijuana iPhone App 3Health News:Coronary CTA a cost-effective alternative to cardiac catheterization for the evaluation of CAD 2
... offers the comfort of a surgical microscope ... The microscope offers brilliant resolution, large depth ... color reproduction. A separate prism for optimum ... with a special jalousie diaphragm. It offers ...
... surgical magnifying loupes are quality surgical ... which provide the healthcare professional a ... depth of field. Each set of ... fully lined wooden box and includes ...
... field-of-view enables high-quality full-coverage body imaging. New ... architecture. New powerful Quasar Dual gradients designed ... to 80 mT/m SR 200. New ... exploit the power of 3.0T in a ...
GE's Signa Contour/i system uses the latest innovations from around the world to bring new standards in quality and value to MRI....
Medicine Products: